Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of erlotinib and pralatrexate that can be given to patients with advanced cancer.
The safety of the drug combination will also be studied.
Pralatrexate is designed to block the body's ability to make folic acid, a protein that may
help cancer tissue to develop and spread.
Erlotinib hydrochloride is designed to block proteins that are thought to cause cancer cells
to grow. Erlotinib may help slow the growth of tumors.